Mindset, founded in 1997, is a rapidly growing biopharmaceutical company which is developing innovative disease-modifying therapies for Alzheimer’s disease and other degenerative conditions of the brain. Mindset’s strength is based on expertise in molecular neuropharmacology, behavioral science, clinical neurology, drug delivery and biopharmaceutical development.

Mindset has two major therapeutic programs in Alzheimer’s disease: a unique small molecule pharmacological approach aimed at reducing amyloid burden and oxidative stress in the brain; and an immunotherapeutic program to immunize and treat patients. The company has also developed a highly specialized platform for drug discovery in transgenic models.

Mindset is led by an outstanding international team who direct its proprietary drug discovery and development programs through preclinical development, human clinical testing and the regulatory process. 

Mindset BioPharmaceuticals (USA) Inc. is a Delaware registered company with subsidiaries in the United States and in Israel. Mindset’s research and development related activities are managed by Mindset BioPharmaceuticals Ltd. located at the company’s headquarters in Jerusalem, Israel.

Sustaining its drug discovery programs, Mindset has developed a unique platform for lead drug candidate selection and optimization using transgenic models to study drug effects in Alzheimer’s disease and other neurodegenerative disorders, including cognitive impairment. This platform has been sublicensed to MindGenix Inc. located in Albany, NY, which provides third-party testing to pharmaceutical companies all over the world. MindGenix's unique capability to test drugs in transgenic models of Alzheimer’s disease and cognitive impairment are rapidly becoming the gold standard for preclinical research in this field. 

Mindset’s research and development activities, its team, including a world-class Scientific Advisory Board, have led to recognition by important organizations supporting Alzheimer’s disease research.  In addition, the company’s ability to grow its innovative product pipeline and to devote the necessary resources to accelerate product development is made possible by strong financial backing, from two leading investment institutions: MPM Capital and Clal Biotechnology Industries.